Loading...
Please wait, while we are loading the content...
Similar Documents
The prognostic value of long noncoding RNAs in prostate cancer: a systematic review and meta-analysis
| Content Provider | Semantic Scholar |
|---|---|
| Author | Ma, Weijie Chen, Xiao Dong Ding, Lu Rong Ma, Jianhong Jing, Wei Lan, Tian Sattar, Haseeb Wei, Yongchang Zhou, Fuling Yuan, Yufeng |
| Copyright Year | 2017 |
| Abstract | The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, we conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into our analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS) (HR = 1.55, 95%CI: 1.01-2.37, P < 0.05), recurrence free survival (RSF) (HR = 3.07, 95%CI: 1.07-8.86, P < 0.05) and progression free survival (PFS) (HR = 2.34, 95%CI: 1.94-2.83, P < 0.001) in PCa patients. LncRNAs expression level was correlated with several vital clinical features, like tumor size (HR = 0.52, 95%CI: 0.28-0.95, P = 0.03), distance metastasis (HR = 4.55, 95%CI: 2.26-9.15, P < 0.0001) and histological grade (HR = 6.23, 95% CI: 3.29-11.82, P < 0.00001). Besides, down-regulation of PCAT14 was associated with the prognosis of PCa [over survival (HR = 0.77, 95%CI: 0.63-0.95, P = 0.01), BCR-FS (HR = 0.61, 95%CI: 0.48-0.79, P = 0.0001), prostate cancer-specific survival (HR = 0.64, 95%CI: 0.48-0.85, P = 0.002) and metastasis-free survival (HR = 0.61, 95%CI: 0.50-0.74, P < 0.00001)]. And, the increased SChLAP1 expression could imply the worse BCR-FS (HR = 2.54, 95%CI: 1.82-3.56, P < 0.00001) and correlate with Gleason score (< 7 vs ≥ 7) (OR = 4.11, 95% CI: 1.94-8.70, P = 0.0002). Conclusively, our present work demonstrated that LncRNAs transcription level might be potential prognostic markers in PCa. |
| Starting Page | 57755 |
| Ending Page | 57765 |
| Page Count | 11 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.oncotarget.com/index.php?journal=oncotarget&op=download&page=article&path%5B%5D=17645&path%5B%5D=56503 |
| PubMed reference number | 28525899v1 |
| Alternate Webpage(s) | https://doi.org/10.18632/oncotarget.17645 |
| DOI | 10.18632/oncotarget.17645 |
| Journal | Oncotarget |
| Volume Number | 8 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Continuance of life Forecast of outcome PCAT14 gene Patients Progression-Free Survival Prostatic Neoplasms RSF1 wt Allele SCHLAP1 gene |
| Content Type | Text |
| Resource Type | Article |
